208
Views
9
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Paper

Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms

, &
Pages 332-337 | Received 15 Jan 2018, Accepted 01 Oct 2018, Published online: 19 Jan 2019

References

  • Bassetti MGF, Mikulska M. New treatment options against Gram-negative organisms. Crit Care. 2011;15(2):215–23.
  • Centers for Disease Control and Prevention [Internet]. Antibiotic resistance threats in the United States 2013. [cited 2017 Dec 1]. Available from: http://www.cdc.gov/drugresistance/threat-report-20132013
  • Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jan 1;48(1):1–12.
  • Bozkurt-Guzel C, Savage PB, Akcali A, Ozbek-Celik B. Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients. Biomed Res Int. 2014;2014:710273.
  • Durnaś B, Piktel E, Wątek M, Wollny T, Góźdź S, Smok-Kalwat J, et al. Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo. BMC Microbiol. 2017;17(1):167–77.
  • Bozkurt-Guzel C, Savage PB, Gerceker AA. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy. 2011;57(6):505–10.
  • Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother. 2008 Feb;61(2):365–70.
  • Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Apr;51(4):1268–73.
  • Hadley EB, Hancock RE. Strategies for the discovery and advancement of novel cationic antimicrobial peptides. Curr Top Med Chem. 2010;10(18):1872–81.
  • Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc Chem Res. 2008;41(10):1233–40.
  • Savage PB, Li C, Taotafa U, Ding B, Guan Q. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett. 2002;217:1–7.
  • Durnaś B, Wnorowska U, Pogoda K, Deptuła P, Wątek M, Piktel E, et al. Candidacidal activity of selected ceragenins and human cathelicidin LL-37 in experimental settings mimicking infection sites. PloS one. 2016;11(6):e0157242.
  • Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM, Savage PB. Susceptibility of colistin-resistant, Gram-negative bacteria to antimicrobial peptides and ceragenins. Antimicrob Agents Chemother. 2017;61(8):e00292–17.
  • Olekson MA, You T, Savage PB, Leung KP. Antimicrobial ceragenins inhibit biofilms and affect mammalian cell viability and migration in vitro. FEBS Open Bio. 2017 Jul;7(7):953–67.
  • Guan Q, Li C, Schmidt EJ, Boswell JS, Walsh JP, Allman GW, et al. Preparation and characterization of cholic acid-derived antimicrobial agents with controlled stabilities. Org Lett. 2000;2(18):2837–40.
  • Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: seventh edition, Approved Standard M7-A7. 2006, Wayne, PA.
  • Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. M100-S22. 2012, Wayne, PA.
  • Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A3. 2008, Wayne, PA.
  • Clinical and Laboratory Standards Institute. Methods for determining bactericidal activity of antimicrobial agents approved guideline, M26-A. 1999, Wayne, PA.
  • Howell MD, Streib JE, Kim BE, Lesley LJ, Dunlap AP, Geng D, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol. 2009 Nov;129(11):2668–75.
  • Lara D, Feng Y, Bader J, Savage PB, Maldonado RA. Anti-trypanosomatid activity of ceragenins. J Parasitol. 2010 Jun;96(3):638–42.
  • Hashemi MM, Holden BS, DurnaAa B, Buck R, Savage PB. Ceragenins as mimics of endogenous antimicrobial peptides. J Antimicrob Agents. 2017;03(02):1233–40.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.